Psylo & CSIRO: A Partnership To Study Neuroplasticity Of New Psychedelic Compounds

Pre-clinical biotech psychedelics company Psylo has signed an agreement with Australia’s national science agency CSIRO to collaboratively investigate the therapeutic potential of the company’s lead drug candidates. Based at the University of New South Wales in Sydney, the company’s goal is to produce highly optimized and proprietary psychedelic therapeutics for current and emerging clinical needs. As an innovation catalyst and through its collaborative research, CSIRO aims at turning science into solutions for health, wellbeing and innovative industries.  In this sense, the national agency will introduce Psylo’s novel compounds to neuronal cell cultures to assess their potential to improve brain function. Measuring neuroplasticity or “the rewiring of neural networks in the brain” is critical for the development of treatments for mental diseases, which are characterized by detrimental structural changes ... Full story available on